EGIS-7229, the new combined class III antiarrhythmic agent Lack of EAD inducing effect

General Pharmacology

Volumn 32, Issue 3, 1999, Pages 329-333

  Bányász, Tamás ^a   Magyar, János ^a   Varró, András ^b   Kovács, Anikó ^c   Gyönös, Ildikó ^c   Szénási, Gábor ^c   Nánási, Péter P ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c EGIS PHARMACEUTICALS LTD   (Hungary)

Author keywords

Action potential duration; Afterdepolarizations; Antiarrhythmic drugs; Cardiac muscle; Electrophysiology

Indexed keywords

5 CHLORO 4 [3 [N [2 (3,4 DIMETHOXYPHENYL)ETHYL] N METHYLAMINO]PROPYLAMINO] 3(2H) PYRIDAZINONE; ADENOSINE DIPHOSPHATE; ANTIARRHYTHMIC AGENT; CESIUM; SOTALOL; UNCLASSIFIED DRUG;

ACTION POTENTIAL; AFTERDISCHARGE; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPOLARIZATION; ELECTROPHYSIOLOGY; HEART PAPILLARY MUSCLE; MICROELECTRODE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; PAPILLARY MUSCLES; PYRIDAZINES; RABBITS; SOTALOL;

EID: 0345434847     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(98)00197-9     Document Type: Article

References (26)

1. Bril A., Forest M.-C., Cheval B., Faivre J.-F. Combined potassium and calcium channel antagonistic activities as a basis for neutral frequency dependent increase in action potential duration. comparison between BRL-32872 and azimilide Cardiovasc Res. 37:1988;130-140.
2. Chezalviel F., Weissenburger J., Guhennec C., Jagueux M., Davy J.M., Vernhet L., Simandoux V., Poirier J.M., Cheymol G. Antiarrhytmic effect of a sotalol-mexiletine combination on induced ventricular tachycardia in dogs. J Cardiovasc Pharmac. 21:1993;212-220.
3. Chezalviel-Guilbet F., Davy J.M., Poirier J.M., Weissenburger J. Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes. J Am Coll Cardiol. 26:1995;787-792.
4. Gwilt M., Arrowsith J.E., Blackburn K.J., Burges R.A., Cross P.E., Dalrymple H.W., Higgins A.J. UK-68798. a novel potent and highly selective Class III antiarrhytmic agent which blocks potassium channels in cardiac cells J Pharmac Exp Ther. 256:1991;318-324.
5. Hafner D., Berger F., Borchard U., Kullmann A., Scherlitz A. Electrophysiological characterization of the class III activity of sotalol and its enantiomers. new interpretation of use-dependent effects Drug Res. 38:1988;231-236.
6. Hoffman B.F., Dangman K.H. Mechanism of cardiac arrhythmias. Experientia. 43:1987;1049-1056.
7. Hondeghem L.M., Snyders D.J. Class III antiarrhythmic agents have a lot of potential but a long way to go. reduced effectiveness and dangers of reverse use dependence Circulation. 81:1990;686-690.
8. Hiromasa S., Coto H., Li Z.-Y., Maldonado C., Kupersmith J. Dextrorotary isomer of sotalol. electrophysiologic effects and interaction with verapamil Am Heart J. 116:1988;1552-1557.
9. Lathrop D.A., Varró A. The combined electrophysiological effects of lignocaine and sotalol in canine isolated cardiac Purkinje fibres are rate-dependent. Br J Pharmac. 99:1990;124-130.
10. Kovács A., Gyönös I., Wellmann J., Nánási P.P., Pankucsi C., Szénási G. Pharmacological effects of EGIS-7229, a new antiarrhytmic compound with combined mode of action. J Mol Cell Cardiol. 28:1996;A59.
11. McVay M.R., Natarajan G., Reddy C.P., Surawicz B. Idiopathic long QT syndrome. association of VT with alternating left and right bundle branch block J Electrocardiol. 15:1982;189-194.
12. Nair L.A., Grant A.O. Emerging class III antiarrhythmic agents. mechanism of action and proarrhythmic potential Cardiovasc Drugs Ther. 11:1997;149-167.
13. Nánási P.P., Pankucsi C., Bányász T., Magyar J., Gyönös I., Kovács A., Szénási G. Electrophysiological properties of EGIS-7229, a new combined antiarrhythmic agent, in mammalian and human cardiac tissues. Cardiovasc Drugs Ther. 11(suppl. 2):1997;318.
14. Nishimura M., Follmer C.H., Singer D.H. Amiodarone blocks calcium current in single guinea pig ventricular myocytes. J Pharmac Exp Ther. 251:1989;650-659.
15. Pankucsi C., Bányász T., Magyar J., Gyönös I., Kovács A., Szénási G., Varró A., Nánási P.P. Electrophysiological effects of EGIS-7229, a new antiarrhythmic agent, in isolated mammalian and human cardiac tissues. Naunyn Schmiedeberg's Arch Pharmac. 355:1997;398-405. a.
16. Pankucsi C., Bányász T., Magyar J., Gyönös I., Kovács A., Szénási G., Varró A., Nánási P.P. Electrophysiological effects of EGIS-7229, a new antiarrhythmic agent, in isolated guinea pig papillary muscle. Gen Pharmac. 29:1997;275-280. b.
17. Protiva, M., 1993. Meeting report of the Fourteenth International Congress of Heterocyclic Chemistry and the Eleventh Symposium on Chemistry of Heterocyclic Compounds. Drug Fut 18, 1143-1150.
18. Singh B.N., Vaughan Williams E.M. The effect of amiodarone, a new antianginal drug on cardiac muscle. Br J Pharmac. 39:1970;657-667.
19. + in canine and guinea pig Purkinje fibers. J Cardiovasc Electrophysiol. 6:1995;796-812.
20. Szénási G., Pankucsi C., Kovács A., Gyönös I., Bányász T., Magyar J., Szilvássy Z., Nánási P.P. Electrophysiological, anti- and proarrhythmic effects of EGIS-7229, a novel antiarrhythmic drug with class III predominance. Eur Heart J. 18S:1997;A254.
21. max in cardiac Purkinje and ventricular muscle fibers. Eur J Pharmac. 112:1985;419-422.
22. Vaughan Williams E.M. Classification of antidysrhythmic drugs. Pharmac Ther B. 1:1975;115-138.
23. Vaughan Williams E.M. Classification of antiarrhythmic actions re-assessed after a decade of new drugs. J Clin Pharmac. 24:1984;129-147. a.
24. Vaughan Williams E.M. Subgroups of class I antiarrhythmic drugs. Eur Heart J. 5:1984;96-98. b.
25. Waldo A.L., Camm A.J., deRuyter H., Freidman P.L., MacNeil D.J., Pitt B., Pratt C.M., Rodda B.E., Schwartz P.J. Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction. rationale, design, and methods (the SWORD trial) Am J Cardiol. 75:1995;1023-1027.
26. Wettwer E., Grundke M., Ravens U. Differential effects of the new class III antiarrhythmic agents almokalant, E-4031 and d-sotalol, and of quinidine, on the delayed rectifier currents in guinea pig ventricular myocytes. Cardiovasc Res. 26:1992;1145-1152.